NCT04949737|Recruiting
Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies
Hélico-MQ
Loading search results
Hélico-MQ
Sponsor study identifier
Secondary identifiers
OTHER · DGS, Ministry of Health
observational
112
1 country
1
Study Start
October 9, 2025
Actual (reported)Primary Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 16, 2021
Actual (reported)July 2, 2021
Actual (reported)October 9, 2025
Actual (reported)April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Estimation of the prevalence of Helicobacter pylori
Helicobacter Pylori has detected by immunohistochemistry in the stomach of patients with gastric cancer.
At baseline
Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup. Additional data will be collected through a questionnaire.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Eligible patients (with a suspected endoscopic diagnosis of gastric cancer) will be selected either at the Martinique University Hospital or at the Sainte-Marie clinic during consultations or hospitalizations.
CHU Martinique
Fort-de-France, 97261, Martinique
Samples retained for extraction of DNA from whole blood
Clarisse JOACHIM-CONTARET
CHU Martinique
First Submitted
June 16, 2021
First Posted
July 2, 2021
Study Start
October 9, 2025
Actual (reported)Primary Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Keverprazan Combined With Amoxicillin for the Treatment of Helicobacter Pylori
Contact the study team to confirm eligibility.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 31, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: